FORMAC Pharmaceuticals announces successful completion of Pre-Clinical Study demonstrating the safety of its proprietary ordered mesoporous silica (MeposilĀ®)

14 June 2011 – FORMAC Pharmaceuticals announces successful completion of Pre-Clinical Study demonstrating the safety of its proprietary ordered mesoporous silica (MeposilĀ®)

No toxicologically significant changes were noted in any of the parameters investigated in the study, (i.e. clinical appearance, functional observations, body weight, food consumption, clinical laboratory investigations, macroscopic examination, organ weights, and microscopic examination).

From the results presented a “No Observed Adverse Effect Level” (NOAEL) for Ordered Mesoporous Silica of at least 5% w/w was established. This corresponds to an estimated mean intake of 4669 and 4707 mg test substance/kg body weight/day for males and females, respectively.